• Report Description
  • Table Of Content
  • Request Methodology

The global nonalcoholic steatohepatitis therapeutics market size is estimated to be USD XXX Million in 2018 and is expected to reach USD XXX Million by 2024, growing at a compound annual growth rate (CAGR) of XX.X% during the forecast period i.e., 2019-2024.

Nonalcoholic Steatohepatitis Therapeutics Market: Growth Drivers

Rise in Number of Cases of Diabetes and Obesity

In the past years, the cases of people suffering from diabetes and obesity have increased at an alarming rate. In the North American region, there is a large population suffering from obesity and diabetes. Not only the adults but the children's are also considered to be suffering from obesity, which has increased almost three times compared to the past year. Due to which there is an increase in demand for treatment of such diseases, which is expected to propel the growth of nonalcoholic steatohepatitis therapeutics over the upcoming years.

Nonalcoholic Steatohepatitis Therapeutics Market: Segmentation Analysis

The nonalcoholic steatohepatitis therapeutics market is segmented by drug type. Based on drug type, the market is segmented into cenicriviroc, emricasan, elafibranor, ocaliva, selonsertib, and others, out of which, elafibranor segment is anticipated to grow at a significant CAGR over the forecast period i.e., 2019-2024. Further, it was followed by ocaliva segment in terms of market share in 2018.

Nonalcoholic Steatohepatitis Therapeutics Market: Geographical Analysis

Geographically, the report offers an analysis of North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In the nonalcoholic steatohepatitis therapeutics market, North America is anticipated to capture a notable market share in 2024. Further, factors such as rise in population suffering from obesity and diabetes in the region are expected to drive the growth of North America nonalcoholic steatohepatitis therapeutics market. Also, the North America market is driven on the back of prevailing cases of high cholesterol and is projected to grow at a noteworthy compound annual growth rate (CAGR) from 2019 to 2024.

Nonalcoholic Steatohepatitis Therapeutics Market: Competitive Analysis

The report also covers detailed competitive analysis of major market players of global nonalcoholic steatohepatitis therapeutics market, such as GENFIT SA, Gilead Sciences, Inc., Immuron Ltd., Astrazeneca Plc, Conatus Pharmaceuticals, Tobira Therapeutics, Inc., Zydus Cadila, Galmed Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Novo Nordisk A/S and other major & niche players. The global nonalcoholic steatohepatitis therapeutics market is witnessing a wide range of industry activities such as product launch, acquisition, partnership, and expansion across the globe.
Segmentation

By Drug Type:
- Cenicriviroc
- Emricasan
- Elafibranor
- Ocaliva
- Selonsertib
- Others

By Geography:
- North America (U.S. & Canada)
- Europe (Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East & Africa (GCC, North Africa, South Africa and Rest of Middle East & Africa)

Competitive Landscape
The report profiles various major market players such as
• GENFIT SA
• Gilead Sciences, Inc.
• Immuron Ltd.
• Astrazeneca Plc
• Conatus Pharmaceuticals
• Tobira Therapeutics, Inc.
• Zydus Cadila
• Galmed Pharmaceuticals Ltd.
• Intercept Pharmaceuticals Inc.
• Novo Nordisk A/S
• Other Major & Niche Players

Competitive landscape analysis provides detailed strategic analysis of the company’s business and performance such as financial information, revenue breakup by segment and by geography, SWOT Analysis, key facts, company overview, business strategy, key product offerings, marketing and distribution strategies, new product development, recent news (acquisition, expansion, technology development, research & development and other market activities).
The study also provides company’s positioning and market share in nonalcoholic steatohepatitis therapeutics market.

Timeline Considered for Analysis:
- 2018: Base Year
- 2019: Estimated Year
- 2019 to 2024: Forecast Period

Research Scope and Deliverables
Overview & Executive Summary
Market Drivers, Trends, Challenges and Opportunities
Market Size and Forecast Projections
Macroeconomic Indicators of Various Countries Impacting the Growth of the Market
Extensive Coverage of Industry Players including Recent Product Launches and Market Activities
Porter’s Five Force Analysis

Market Segmentation Analysis:
Industry report analyzes the global nonalcoholic steatohepatitis therapeutics market by the following segments:
- Drug Type

Customization: We also offers customization’s in the industry report as per the company’s specific needs.

Key Questions Answered in the Global Nonalcoholic Steatohepatitis Therapeutics Industry Report
• What is the overall market size in 2018? What will be the market growth during the forecast period i.e. 2019-2024?
• Which region would have high demand for product in the upcoming years?
• What are the factors driving the growth of the market?
• Which sub-market will make the most significant contribution to the market?
• What are the market opportunities for existing and entry-level players?
• What are various long-term and short-term strategies adopted by the market players?

Research Methodology
Market Definition and List of Abbreviations
1. Executive Summary
2. Growth Drivers & Barriers in Global Nonalcoholic Steatohepatitis Therapeutics Market
3. Global Nonalcoholic Steatohepatitis Therapeutics Market Trends
4. Opportunities in Global Nonalcoholic Steatohepatitis Therapeutics Market
5. Recent Industry Activities
6. Porter's Five Forces Analysis
7. Market Value Chain Analysis
8. Global Nonalcoholic Steatohepatitis Therapeutics Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024

9. Global Nonalcoholic Steatohepatitis Therapeutics Market Segmentation Analysis, By Drug Type
9.1. Introduction
9.2. Market Attractiveness, By Drug Type
9.3. BPS Analysis, By Drug Type
9.4. Cenicriviroc Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
9.5. Emricasan Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
9.6. Elafibranor Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
9.7. Ocaliva Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
9.8. Selonsertib Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
9.9. Others Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024

10. Geographical Analysis
10.1. Introduction
10.2. North America Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.2.1. By Drug Type
10.2.1.1. Introduction
10.2.1.2. Market Attractiveness, By Drug Type
10.2.1.3. BPS Analysis, By Drug Type
10.2.1.4. Cenicriviroc Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.2.1.5. Emricasan Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.2.1.6. Elafibranor Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.2.1.7. Ocaliva Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.2.1.8. Selonsertib Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.2.1.9. Others Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.2.2. By Country
10.2.2.1. Introduction
10.2.2.2. Market Attractiveness, By Country
10.2.2.3. BPS Analysis, By Country
10.2.2.4. U.S. Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.2.2.5. Canada Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024

10.3. Europe Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.3.1. By Drug Type
10.3.1.1. Introduction
10.3.1.2. Market Attractiveness, By Drug Type
10.3.1.3. BPS Analysis, By Drug Type
10.3.1.4. Cenicriviroc Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.3.1.5. Emricasan Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.3.1.6. Elafibranor Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.3.1.7. Ocaliva Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.3.1.8. Selonsertib Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.3.1.9. Others Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.3.2. By Country
10.3.2.1. Introduction
10.3.2.2. Market Attractiveness, By Country
10.3.2.3. BPS Analysis, By Country
10.3.2.4. Germany Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.3.2.5. United Kingdom Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.3.2.6. France Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.3.2.7. Italy Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.3.2.8. Spain Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.3.2.9. Russia Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.3.2.10. Rest of Europe Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024

10.4. Asia Pacific Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.1. By Drug Type
10.4.1.1. Introduction
10.4.1.2. Market Attractiveness, By Drug Type
10.4.1.3. BPS Analysis, By Drug Type
10.4.1.4. Cenicriviroc Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.1.5. Emricasan Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.1.6. Elafibranor Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.1.7. Ocaliva Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.1.8. Selonsertib Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.1.9. Others Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.2. By Country
10.4.2.1. Introduction
10.4.2.2. Market Attractiveness, By Country
10.4.2.3. BPS Analysis, By Country
10.4.2.4. China Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.2.5. India Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.2.6. Japan Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.2.7. Australia Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.2.8. South Korea Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.2.9. Indonesia Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.2.10. Thailand Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.2.11. New Zealand Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.4.2.12. Rest of Asia Pacific Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024

10.5. Latin America Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.5.1. By Drug Type
10.5.1.1. Introduction
10.5.1.2. Market Attractiveness, By Drug Type
10.5.1.3. BPS Analysis, By Drug Type
10.5.1.4. Cenicriviroc Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.5.1.5. Emricasan Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.5.1.6. Elafibranor Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.5.1.7. Ocaliva Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.5.1.8. Selonsertib Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.5.1.9. Others Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.5.2. By Country
10.5.2.1. Introduction
10.5.2.2. Market Attractiveness, By Country
10.5.2.3. BPS Analysis, By Country
10.5.2.4. Brazil Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.5.2.5. Mexico Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.5.2.6. Rest of Latin America Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024

10.6. The Middle East & Africa Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.6.1. By Drug Type
10.6.1.1. Introduction
10.6.1.2. Market Attractiveness, By Drug Type
10.6.1.3. BPS Analysis, By Drug Type
10.6.1.4. Cenicriviroc Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.6.1.5. Emricasan Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.6.1.6. Elafibranor Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.6.1.7. Ocaliva Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.6.1.8. Selonsertib Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.6.1.9. Others Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.6.2. By Geography
10.6.2.1. Introduction
10.6.2.2. Market Attractiveness, By Geography
10.6.2.3. BPS Analysis, By Geography
10.6.2.4. GCC Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.6.2.5. North Africa Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.6.2.6. South Africa Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024
10.6.2.7. Rest of Middle East & Africa Market Value (USD Million) Forecast & Y-o-Y Growth Analysis, 2018-2024

11. Competitive Landscape
11.1. Market Share of Key Players
11.2. Market Positioning of Major Players in Global Nonalcoholic Steatohepatitis Therapeutics Market
11.3. Company Profiles
11.3.1. GENFIT SA
11.3.2. Gilead Sciences, Inc.
11.3.3. Immuron Ltd.
11.3.4. Astrazeneca Plc
11.3.5. Conatus Pharmaceuticals
11.3.6. Tobira Therapeutics, Inc.
11.3.7. Zydus Cadila
11.3.8. Galmed Pharmaceuticals Ltd.
11.3.9. Intercept Pharmaceuticals Inc.
11.3.10. Novo Nordisk A/S
11.3.11. Other Major & Niche Players

Select License Type
  • Single User License $3375 USD
  • Multi-User License $4185 USD
  • Corporate User License $4815 USD

Request For Customization



Request Customization

Check Discount



Request Discount

Corporate Clients

More than 200 Clients